{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:57:27Z","timestamp":1791615447406,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T00:00:00Z","timestamp":1536278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>In randomized clinical trials (<jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s) proprotein convertase subtilisin\/kexin 9 (<jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9) inhibitors showed a favorable safety profile, however, \u201creal\u2010world\u201d data on adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) is scarce. Three datasets, a hospital registry (<jats:italic>n<\/jats:italic>\u00a0=\u00a0164), and two Pharmacovigilance databases, Lareb (<jats:italic>n<\/jats:italic>\u00a0=\u00a0149) and VigiLyze (<jats:italic>n<\/jats:italic>\u00a0=\u00a015,554), reporting <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s attributed to <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9 inhibitors (alirocumab or evolocumab) prescribed in clinical practice were analyzed. In the hospital registry, 41.5% of the patients reported any <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>, most often injection\u2010site reactions (33.8%) and influenza\u2010like illness (27.9%). Twelve patients (7%) discontinued <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9 inhibitor treatment. Most common <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> reported in the Lareb and VigiLyze database was myalgia (12.8% and 8.3%, respectively). No clinically relevant differences in gender or between drugs were observed. No specific subgroup of patients could be identified at risk of developing <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s. During follow\u2010up, <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s resolved in most patients (71.1%). In a real\u2010world setting, <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9 inhibitors are well tolerated with an overall safety profile comparable to <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s.<\/jats:p>","DOI":"10.1002\/cpt.1193","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T16:19:03Z","timestamp":1532708343000},"page":"496-504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Adverse Events Associated With <scp>PCSK<\/scp>9 Inhibitors: A Real\u2010World Experience"],"prefix":"10.1111","volume":"105","author":[{"given":"Muhammed T.","family":"G\u00fcrg\u00f6ze","sequence":"first","affiliation":[{"name":"Erasmus MC University Medical Centre Rotterdam Department of Cardiology  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie H.G.","family":"Muller\u2010Hansma","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  \u2018s\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Schreuder","sequence":"additional","affiliation":[{"name":"Erasmus MC University Medical Centre Rotterdam Department of Internal Medicine  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.H.","family":"Galema\u2010Boers","sequence":"additional","affiliation":[{"name":"Erasmus MC University Medical Centre Rotterdam Department of Internal Medicine  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Boersma","sequence":"additional","affiliation":[{"name":"Erasmus MC University Medical Centre Rotterdam Department of Cardiology  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[{"name":"Erasmus MC University Medical Centre Rotterdam Department of Internal Medicine  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"e_1_2_14_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx549"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2016.03.002"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_14_6_1","first-page":"w14094","article-title":"PCSK9 inhibitors","volume":"145","author":"Gencer B.","year":"2015","journal-title":"Swiss Med. Wkly."},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.07.922"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0358-8"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.703579"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00817.x"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2002.00100.x"},{"key":"e_1_2_14_14_1","unstructured":"Zorginstituut Nederland.GIP databank. (version date: 2017). <https:\/\/www.gipdatabank.nl> (2017). Accessed 29 November 2017."},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.08.072"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025233"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006910"},{"issue":"4","key":"e_1_2_14_18_1","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","author":"Schmidt A.F.","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0493-7"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.02.014"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13032"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000424"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2017.0137"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.01.044"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.2.7909"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07339_supp.x"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.037"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701131"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx661"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307071"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.003153"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv563"},{"key":"e_1_2_14_34_1","unstructured":"U. S. Food and Drug Administration.Summary review: BLA# 125559. <https:\/\/www.fda.gov\/> (2014)."},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3655"},{"key":"e_1_2_14_37_1","unstructured":"The Netherlands pharmacovigilance centre Lareb database(version date: 2017). <www.lareb.nl> (2017). Accessed 26 September 2017."},{"key":"e_1_2_14_38_1","unstructured":"WHO Global Individual Case Safety Reports database (VigiLyze). (version date: 2017). <https:\/\/tools.who-umc.org\/webroot\/> (access restricted). (2017). Accessed 21 November 2017."},{"key":"e_1_2_14_39_1","unstructured":"Zorginstituut Nederland.GVS rapport. Farmaco\u2010Economisch rapport voor evolocumab (Repatha\u00ae) bij de behandeling van hypercholesterolemie 1\u2010111. <https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2015\/12\/14\/evolocumabrepatha-bij-hypercholesterolemie-en-gemengde-dyslipidemiehomozygotefamiliaire-hypercholesterolemie> (2015)."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:29:19Z","timestamp":1699363759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/cpt.1193"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1193","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]},"assertion":[{"value":"2018-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}